Erasca Expands License Agreement with Joyo to Include China, Hong Kong, and Macau
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ERAS?
Erasca announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, which will provide Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015. Under the terms of the ERAS-0015 license agreement, Erasca exercised its option to convert its territory to worldwide and is obligated to make a one-time payment to Joyo based on the stage of Joyo's development program. Securing rights in China, Hong Kong, and Macau will provide Erasca with exclusive global rights for ERAS-0015, enabling the company to pursue a unified worldwide development and commercialization strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 15.500
Low
2.00
Averages
5.50
High
11.00
Current: 15.500
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- OKTA Stock Outlook: Analysts' perspectives on OKTA stock have garnered attention, prompting investors to consider these rating changes when contemplating purchases for more informed investment choices.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly affect stock prices, necessitating that investors closely monitor these changes to seize market opportunities.
- Comprehensive Analysis View: For a complete overview of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page for more detailed information and data.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Erasca Stock Declines Without News Justification
- Stock Decline: Erasca Inc. (NASDAQ:ERAS) shares fell 7.13% to $9.25 on Monday, despite no news justifying the decline, indicating market concerns about its future performance.
- 52-Week Range: The stock is trading near the upper end of its 52-week range of $1.01 to $10.67, reflecting investor apprehension regarding its volatility and potential risks, which could impact its fundraising capabilities and market confidence.
- Acquisition Talks End: Merck & Co. (NYSE:MRK) reportedly ended discussions to acquire Revolution Medicines (NASDAQ:RVMD) due to valuation disagreements, raising concerns about future M&A activities in the oncology sector.
- Funding Plans: Last week, Erasca priced an upsized public offering of 22.5 million shares at $10.00 each, aiming to raise $225 million to fund R&D and other corporate purposes, although the current stock decline may affect its financing outlook.
See More
Intuitive Surgical (ISRG) Reports Q4 Revenue of $2.87 Billion, Exceeding Expectations
- Earnings Beat: Intuitive Surgical reported Q4 revenue of approximately $2.87 billion and adjusted earnings of $2.53 per share, both exceeding analyst expectations, driven by year-over-year growth in procedure volume and robotic system placements, leading to a rise in after-hours trading.
- Dividend Increase: Kinder Morgan topped Q4 revenue expectations with about $4.51 billion and adjusted earnings of $0.39 per share, while announcing a 2% quarterly dividend increase to $0.2925 per share, despite slightly lowering its 2026 earnings outlook, reflecting cautious sentiment amid ongoing energy market dynamics.
- Expansion Plans: USA Rare Earth announced plans to establish a high-capacity metal and alloy production plant in Lacq, France, capable of producing about 3,750 metric tons per year through its subsidiary Less Common Metals, aimed at strengthening transatlantic supply chains and boosting investor optimism.
- Market Volatility: Despite subdued overall market performance, small-cap benchmarks reached new highs, indicating sustained investor demand for risk assets against a backdrop of easing geopolitical tensions, which positively influenced the performance of certain tech stocks.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- OKTA Stock Outlook: Analysts' perspectives on OKTA stock have garnered attention, prompting investors to consider these rating changes when contemplating purchases for more informed investment choices.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly affect stock prices, necessitating that investors closely monitor these changes to seize market opportunities.
- Comprehensive Analysis View: For a complete overview of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page for more detailed information and data.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Erasca Stock Declines Without News Justification
- Stock Decline: Erasca Inc. (NASDAQ:ERAS) shares fell 7.13% to $9.25 on Monday, despite no news justifying the decline, indicating market concerns about its future performance.
- 52-Week Range: The stock is trading near the upper end of its 52-week range of $1.01 to $10.67, reflecting investor apprehension regarding its volatility and potential risks, which could impact its fundraising capabilities and market confidence.
- Acquisition Talks End: Merck & Co. (NYSE:MRK) reportedly ended discussions to acquire Revolution Medicines (NASDAQ:RVMD) due to valuation disagreements, raising concerns about future M&A activities in the oncology sector.
- Funding Plans: Last week, Erasca priced an upsized public offering of 22.5 million shares at $10.00 each, aiming to raise $225 million to fund R&D and other corporate purposes, although the current stock decline may affect its financing outlook.
See More
Intuitive Surgical (ISRG) Reports Q4 Revenue of $2.87 Billion, Exceeding Expectations
- Earnings Beat: Intuitive Surgical reported Q4 revenue of approximately $2.87 billion and adjusted earnings of $2.53 per share, both exceeding analyst expectations, driven by year-over-year growth in procedure volume and robotic system placements, leading to a rise in after-hours trading.
- Dividend Increase: Kinder Morgan topped Q4 revenue expectations with about $4.51 billion and adjusted earnings of $0.39 per share, while announcing a 2% quarterly dividend increase to $0.2925 per share, despite slightly lowering its 2026 earnings outlook, reflecting cautious sentiment amid ongoing energy market dynamics.
- Expansion Plans: USA Rare Earth announced plans to establish a high-capacity metal and alloy production plant in Lacq, France, capable of producing about 3,750 metric tons per year through its subsidiary Less Common Metals, aimed at strengthening transatlantic supply chains and boosting investor optimism.
- Market Volatility: Despite subdued overall market performance, small-cap benchmarks reached new highs, indicating sustained investor demand for risk assets against a backdrop of easing geopolitical tensions, which positively influenced the performance of certain tech stocks.
See More
